Published in Int J Tuberc Lung Dis on February 01, 2008
Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med (2012) 5.87
Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet (2009) 5.30
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med (2014) 5.23
High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet (2011) 4.73
The challenge of new drug discovery for tuberculosis. Nature (2011) 4.23
Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J (2014) 2.28
Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med (2009) 2.18
Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother (2011) 1.99
Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother (2012) 1.83
Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob Agents Chemother (2009) 1.82
Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis. Am J Respir Crit Care Med (2013) 1.65
Targeting persisters for tuberculosis control. Antimicrob Agents Chemother (2012) 1.65
Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials. BMC Med (2016) 1.61
The chemotherapy of tuberculosis: past, present and future. Int J Tuberc Lung Dis (2012) 1.61
New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother (2008) 1.50
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis. Antimicrob Agents Chemother (2014) 1.41
Geographic differences in time to culture conversion in liquid media: Tuberculosis Trials Consortium study 28. Culture conversion is delayed in Africa. PLoS One (2011) 1.38
An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse. PLoS One (2013) 1.36
Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrob Agents Chemother (2010) 1.36
Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother (2012) 1.33
Pyrosequencing for rapid detection of Mycobacterium tuberculosis resistance to rifampin, isoniazid, and fluoroquinolones. J Clin Microbiol (2009) 1.32
Month 2 culture status and treatment duration as predictors of tuberculosis relapse risk in a meta-regression model. PLoS One (2013) 1.30
A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis. Bioorg Med Chem Lett (2013) 1.25
Comparative study on genotypic and phenotypic second-line drug resistance testing of Mycobacterium tuberculosis complex isolates. J Clin Microbiol (2010) 1.22
Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistance. J Antimicrob Chemother (2009) 1.19
Systematic review of allelic exchange experiments aimed at identifying mutations that confer drug resistance in Mycobacterium tuberculosis. J Antimicrob Chemother (2013) 1.19
Structural insights into quinolone antibiotic resistance mediated by pentapeptide repeat proteins: conserved surface loops direct the activity of a Qnr protein from a gram-negative bacterium. Nucleic Acids Res (2011) 1.18
Baseline predictors of sputum culture conversion in pulmonary tuberculosis: importance of cavities, smoking, time to detection and W-Beijing genotype. PLoS One (2012) 1.15
Current development and future prospects in chemotherapy of tuberculosis. Respirology (2010) 1.12
Evaluation of time to detection of Mycobacterium tuberculosis in broth culture as a determinant for end points in treatment trials. J Clin Microbiol (2010) 1.11
Tuberculosis pharmacotherapy: strategies to optimize patient care. Expert Opin Pharmacother (2009) 1.08
Molecular bacterial load assay, a culture-free biomarker for rapid and accurate quantification of sputum Mycobacterium tuberculosis bacillary load during treatment. J Clin Microbiol (2011) 1.05
Mycobacterium tuberculosis DNA repair in response to subinhibitory concentrations of ciprofloxacin. J Antimicrob Chemother (2008) 1.05
Investigational antimicrobial agents of 2013. Clin Microbiol Rev (2013) 1.04
Pipeline of drugs for related diseases: tuberculosis. Curr Opin HIV AIDS (2013) 1.04
Month 2 culture status and treatment duration as predictors of recurrence in pulmonary tuberculosis: model validation and update. PLoS One (2015) 1.01
A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lessons learnt from the Gatifloxacin for TB (OFLOTUB) project. Trials (2012) 1.01
Gatifloxacin induces S and G2-phase cell cycle arrest in pancreatic cancer cells via p21/p27/p53. PLoS One (2012) 0.99
High proportion of fluoroquinolone-resistant Mycobacterium tuberculosis isolates with novel gyrase polymorphisms and a gyrA region associated with fluoroquinolone susceptibility. J Clin Microbiol (2011) 0.98
A time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culture. Antimicrob Agents Chemother (2012) 0.97
Fluoroquinolone and quinazolinedione activities against wild-type and gyrase mutant strains of Mycobacterium smegmatis. Antimicrob Agents Chemother (2011) 0.97
Current prospects for the fluoroquinolones as first-line tuberculosis therapy. Antimicrob Agents Chemother (2011) 0.96
The molecular bacterial load assay replaces solid culture for measuring early bactericidal response to antituberculosis treatment. J Clin Microbiol (2014) 0.96
Pharmacodynamic Modeling of Bacillary Elimination Rates and Detection of Bacterial Lipid Bodies in Sputum to Predict and Understand Outcomes in Treatment of Pulmonary Tuberculosis. Clin Infect Dis (2015) 0.95
In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species. Antimicrob Agents Chemother (2010) 0.94
Evaluation of moxifloxacin-containing regimens in pathologically distinct murine tuberculosis models. Antimicrob Agents Chemother (2015) 0.92
Doubts about DOTS. BMJ (2008) 0.92
New approaches in the diagnosis and treatment of latent tuberculosis infection. Respir Res (2010) 0.92
Recent advances in tuberculosis: New drugs and treatment regimens. Curr Respir Med Rev (2013) 0.91
Assessment of the Efficacy of New Anti-Tuberculosis Drugs. Open Infect Dis J (2008) 0.91
Optimizing outpatient serial sputum colony counting for studies of tuberculosis treatment in resource-poor settings. J Clin Microbiol (2012) 0.89
More efficient ways of assessing treatments for neglected tropical diseases are required: innovative study designs, new endpoints, and markers of effects. PLoS Negl Trop Dis (2012) 0.86
In vitro model of mycobacterial growth arrest using nitric oxide with limited air. Antimicrob Agents Chemother (2008) 0.86
Shortening Tuberculosis Treatment With Fluoroquinolones: Lost in Translation? Clin Infect Dis (2015) 0.84
The role of delamanid in the treatment of drug-resistant tuberculosis. Ther Clin Risk Manag (2015) 0.83
Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations. Antimicrob Agents Chemother (2013) 0.82
New Antituberculosis Drugs: From Clinical Trial to Programmatic Use. Infect Dis Rep (2016) 0.81
Molecular detection of fluoroquinolone-resistance in multi-drug resistant tuberculosis in Cambodia suggests low association with XDR phenotypes. BMC Infect Dis (2011) 0.81
Drug Resistance Mechanisms in Mycobacterium tuberculosis. Antibiotics (Basel) (2014) 0.80
Inhibiting Mycobacterium tuberculosis within and without. Philos Trans R Soc Lond B Biol Sci (2016) 0.80
Respiratory review of 2014: tuberculosis and nontuberculous mycobacterial pulmonary disease. Tuberc Respir Dis (Seoul) (2014) 0.80
Antituberculosis therapy for 2012 and beyond. Expert Opin Pharmacother (2012) 0.80
A Bayesian Nonlinear Mixed-Effects Regression Model for the Characterization of Early Bactericidal Activity of Tuberculosis Drugs. J Biopharm Stat (2014) 0.79
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis (2016) 0.79
Effects of Fluroquinolones in Newly Diagnosed, Sputum-Positive Tuberculosis Therapy: A Systematic Review and Network Meta-Analysis. PLoS One (2015) 0.79
Moxifloxacin and gatifloxacin for initial therapy of tuberculosis: a meta-analysis of randomized clinical trials. Emerg Microbes Infect (2016) 0.78
A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis. PLoS One (2016) 0.78
Application of the Multistate Tuberculosis Pharmacometric Model in Patients With Rifampicin-Treated Pulmonary Tuberculosis. CPT Pharmacometrics Syst Pharmacol (2016) 0.78
Activity of the fluoroquinolone DC-159a in the initial and continuation phases of treatment of murine tuberculosis. Antimicrob Agents Chemother (2011) 0.78
Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients. Antimicrob Agents Chemother (2013) 0.78
Tuberculosis drug development: ensuring people living with HIV are not left behind. Am J Respir Crit Care Med (2011) 0.78
New drugs to treat tuberculosis. F1000 Med Rep (2012) 0.78
A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way. Clin Infect Dis (2016) 0.78
New drugs and regimens for treatment of TB. Expert Rev Anti Infect Ther (2010) 0.77
Drug-resistant tuberculosis: emerging treatment options. Clin Pharmacol (2011) 0.76
Exploring prospects of novel drugs for tuberculosis. Drug Des Devel Ther (2012) 0.76
Challenges in the clinical assessment of novel tuberculosis drugs. Adv Drug Deliv Rev (2016) 0.76
Accumulating Evidence and Research Organization (AERO) model: a new tool for representing, analyzing, and planning a translational research program. Trials (2013) 0.76
Therapeutic effect of a novel oxazolidinone, DA-7867, in BALB/c mice infected with Nocardia brasiliensis. PLoS Negl Trop Dis (2008) 0.75
The Effectiveness and Safety of Fluoroquinolone-Containing Regimen as a First-Line Treatment for Drug-Sensitive Pulmonary Tuberculosis: A Systematic Review and Meta-Analysis. PLoS One (2016) 0.75
Current Status of Fluoroquinolone Use for Treatment of Tuberculosis in a Tertiary Care Hospital in Korea. Tuberc Respir Dis (Seoul) (2017) 0.75
Quality of outcome reporting in phase II studies in pulmonary tuberculosis. Trials (2015) 0.75
Survival in XDR TB: shifting the curve and shifting the paradigm. J Acquir Immune Defic Syndr (2011) 0.75
Pharmacologic considerations in use and development of antituberculosis drugs. Cold Spring Harb Perspect Med (2014) 0.75
Efficacy of ultra-short course chemotherapy for new smear positive drug susceptible pulmonary tuberculosis: study protocol of a multicenter randomized controlled clinical trial. BMC Infect Dis (2017) 0.75
Mathematical Models of Tuberculosis Reactivation and Relapse. Front Microbiol (2016) 0.75
Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ (1969) 12.55
WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J (2011) 8.96
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet (2009) 7.96
Impact of stepping stones on incidence of HIV and HSV-2 and sexual behaviour in rural South Africa: cluster randomised controlled trial. BMJ (2008) 7.63
A selective oleic acid albumin agar medium for tubercle bacilli. J Med Microbiol (1972) 6.78
Detection of endotoxin in human blood and demonstration of an inhibitor. J Lab Clin Med (1970) 6.04
Antigenic diversity of Mycobacterium tuberculosis and Mycobacterium bovis detected by means of monoclonal antibodies. Lancet (1981) 6.01
The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis (1980) 4.69
Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis (1999) 4.52
Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet (1998) 3.97
Clottable protein in Limulus; its localization and kinetics of its coagulation by endotoxin. Thromb Diath Haemorrh (1968) 3.90
The action of antituberculosis drugs in short-course chemotherapy. Tubercle (1985) 3.69
Detection of endotoxin in the blood of patients with sepsis due to gran-negative bacteria. N Engl J Med (1970) 3.55
Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis (1986) 3.46
Consultation patterns and provision of contraception in general practice before teenage pregnancy: case-control study. BMJ (2000) 3.41
Treatment failure due to extended spectrum beta-lactamase. J Antimicrob Chemother (1996) 3.20
Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore) (1977) 3.20
Timing of relapse in short-course chemotherapy trials for tuberculosis. Int J Tuberc Lung Dis (2010) 3.07
Factors associated with HIV sero-status in young rural South African women: connections between intimate partner violence and HIV. Int J Epidemiol (2006) 3.07
The increasing burden of tuberculosis in rural South Africa--impact of the HIV epidemic. S Afr Med J (1997) 3.06
5-Methylcytosine localised in mammalian constitutive heterochromatin. Nature (1974) 3.06
Theoretical framework for spectrum analysis in ultrasonic tissue characterization. J Acoust Soc Am (1983) 3.01
Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis (1993) 3.01
Hemolytic-uremic syndrome after shigellosis. Relation to endotoxemia and circulating immune complexes. N Engl J Med (1978) 2.95
Failure of the International Normalized Ratio to generate consistent results within a local medical community. Am J Clin Pathol (1993) 2.81
Gram-negative sepsis: detection of endotoxemia with the limulus test. With studies of associated changes in blood coagulation, serum lipids, and complement. Ann Intern Med (1972) 2.79
Diagnosing tuberculosis in a resource-poor setting: the value of sputum concentration. Trans R Soc Trop Med Hyg (1997) 2.70
A cluster randomized-controlled trial to determine the effectiveness of Stepping Stones in preventing HIV infections and promoting safer sexual behaviour amongst youth in the rural Eastern Cape, South Africa: trial design, methods and baseline findings. Trop Med Int Health (2006) 2.64
Sulphadimidine acetylation test for classification of patients as slow or rapid inactivators of isoniazid. Br Med J (1970) 2.61
Selective Kirchner medium in the culture of specimens other than sputum for mycobacteria. J Clin Pathol (1983) 2.61
An invertebrate coagulation system activated by endotoxin: evidence for enzymatic mediation. J Clin Invest (1972) 2.61
Short-course chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis (1975) 2.59
Association between teenage pregnancy rates and the age and sex of general practitioners: cross sectional survey in Trent 1994-7. BMJ (2000) 2.58
Correlation of the highest-energy cosmic rays with nearby extragalactic objects. Science (2007) 2.57
The use of murine monoclonal antibodies without purification of antigen in the serodiagnosis of tuberculosis. J Immunol Methods (1982) 2.57
Quality control in tuberculosis bacteriology. 1. Laboratory studies on isolated positive cultures and the efficiency of direct smear examination. Tubercle (1980) 2.57
Hematocrit value on intensive care unit entry influences the frequency of Q-wave myocardial infarction after coronary artery bypass grafting. The Institutions of the Multicenter Study of Perioperative Ischemia (McSPI) Research Group. J Thorac Cardiovasc Surg (1998) 2.49
Mechanisms of contrast agent destruction. IEEE Trans Ultrason Ferroelectr Freq Control (2001) 2.48
A reevaluation of the role of crystalloid preload in the prevention of hypotension associated with spinal anesthesia for elective cesarean section. Anesthesiology (1993) 2.44
Molecular subtyping of Treponema pallidum subspecies pallidum. Sex Transm Dis (1998) 2.44
Arc-scanning very high-frequency digital ultrasound for 3D pachymetric mapping of the corneal epithelium and stroma in laser in situ keratomileusis. J Refract Surg (2000) 2.40
CD36 gene transfer confers capacity for phagocytosis of cells undergoing apoptosis. J Exp Med (1995) 2.34
Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother (2008) 2.33
Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis. Am Rev Respir Dis (1981) 2.31
Do the attitudes and beliefs of young teenagers towards general practice influence actual consultation behaviour? Br J Gen Pract (2000) 2.29
Reliability of ocular and orbital diagnosis with B-scan ultrasound. 1. Ocular diagnosis. Am J Ophthalmol (1972) 2.28
Preoperative vaginal bacteria and postoperative infections in gynaecological patients. Lancet (1973) 2.25
Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg (1997) 2.23
Selective media in the isolation of tubercle bacilli from tissues. J Clin Pathol (1973) 2.17
Can autism be detected at 18 months? The needle, the haystack, and the CHAT. Br J Psychiatry (1992) 2.16
The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment. J Antimicrob Chemother (1993) 2.12
Prevalence of emotional, physical and sexual abuse of women in three South African provinces. S Afr Med J (2001) 2.09
Quantitative comparison of in vitro and in vivo methods for the detection of endotoxin. J Lab Clin Med (1971) 2.08
Anaerobic degradation of polycyclic aromatic hydrocarbons and alkanes in petroleum-contaminated marine harbor sediments. Appl Environ Microbiol (1997) 2.06
Replication and extension of Marlatt's taxonomy of relapse precipitants: overview of procedures and results. The Relapse Research Group. Addiction (1996) 2.04
Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide. J Bacteriol (2000) 2.03
A critical reappraisal of the bleeding time. Semin Thromb Hemost (1990) 2.03
The hematopoietically expressed vav proto-oncogene shares homology with the dbl GDP-GTP exchange factor, the bcr gene and a yeast gene (CDC24) involved in cytoskeletal organization. Oncogene (1992) 2.02
Basic mechanisms of chemotherapy. Chest (1979) 2.01
Controlled clinical trial of complete open surgical drainage and of prednisolone in treatment of tuberculous pericardial effusion in Transkei. Lancet (1988) 1.99
The natural history of stroke in sickle cell disease. Am J Med (1978) 1.97
Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide. Antimicrob Agents Chemother (1996) 1.97
The RNA code and protein synthesis. Cold Spring Harb Symp Quant Biol (1966) 1.96
Application of DNA fingerprinting with IS986 to sequential mycobacterial isolates obtained from pulmonary tuberculosis patients in Hong Kong before, during and after short-course chemotherapy. Tuber Lung Dis (1993) 1.94
Isoniazid preventive therapy for people living with HIV: public health challenges and implementation issues. Int J Tuberc Lung Dis (2009) 1.92
Ten-year study of pediatric drownings and near-drownings in King County, Washington: lessons in injury prevention. Pediatrics (1989) 1.92
Factors associated with HIV sero-positivity in young, rural South African men. Int J Epidemiol (2006) 1.90
A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. J Antimicrob Chemother (2000) 1.90
Cancer-related fatigue: A critical appraisal. Eur J Cancer (2006) 1.90
The social ecology of health promotion: implications for research and practice. Am J Health Promot (1996) 1.89
Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients. Antimicrob Agents Chemother (1996) 1.87
Hemoglobin infusion augments the tumor necrosis factor response to bacterial endotoxin (lipopolysaccharide) in mice. Crit Care Med (1999) 1.87
The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid. Clin Infect Dis (2004) 1.87
A computer-assisted bacteriology reporting and information system. J Clin Pathol (1978) 1.86
Careers in academic general practice: problems, constraints, and opportunities. BMJ (1994) 1.83
Thrombocytopenia with absent radius (TAR). Medicine (Baltimore) (1969) 1.82
Depression and multiple sclerosis. Neurology (1996) 1.79
The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. Am J Respir Crit Care Med (1997) 1.76
Expression of Hox-2.4 homeobox gene directed by proviral insertion in a myeloid leukemia. Nucleic Acids Res (1989) 1.74
Tuberculosis contacts but not patients have higher gamma interferon responses to ESAT-6 than do community controls in The Gambia. Infect Immun (2001) 1.74
Diagnostic spectrum analysis in ophthalmology: a physical perspective. Ultrasound Med Biol (1986) 1.73
A further consideration in the application of an analysis-of-variance model for the intrasubject replication design. J Appl Behav Anal (1974) 1.73
Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures. Int J Tuberc Lung Dis (2002) 1.73
Direct-recorded intraocular pressure variations in a human subject. Arch Ophthalmol (1969) 1.71
An effective method of RNA extraction from bacteria refractory to disruption, including mycobacteria. Nucleic Acids Res (1997) 1.69
A hand-operated, ultrasound scan system for ophthalmic evaluation. Am J Ophthalmol (1969) 1.69
Primary drug resistance in pulmonary tuberculosis in Great Britain: second national survey, 1963. Tubercle (1966) 1.65
Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits. Nat Med (1999) 1.64
Early bactericidal activity of antituberculosis agents. Expert Rev Anti Infect Ther (2003) 1.64
Molecular epidemiology and transmission dynamics of Mycobacterium tuberculosis in rural Africa. Trop Med Int Health (1997) 1.64
Integrating a 1.5 T MRI scanner with a 6 MV accelerator: proof of concept. Phys Med Biol (2009) 1.63
The puzzle of "urethral syndrome": a possible answer? Lancet (1979) 1.63
Whole-cell and single-channel calcium currents of isolated smooth muscle cells from saphenous vein. Circ Res (1987) 1.63
Unified model for accommodative mechanism. Am J Ophthalmol (1970) 1.62